Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2025
Business Overview: Autonomix is a pre-revenue, clinical-stage medical device company developing a catheter-based microchip-enabled sensing array to detect and treat disorders of the peripheral nervous system. The company is initially focused on treating pain associated with pancreatic cancer via transvascular nerve ablation. It operates as a single segment business and is classified as an "emerging growth company" and a "smaller reporting company."
Key Financial Metrics
| Metric (in thousands) | Year Ended March 31, 2025 | Year Ended March 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(11,410) | $(15,426) |
| Operating Expenses | $11,588 | $12,030 |
| Cash and Cash Equivalents (Ending) | $9,136 | $8,608 |
| Working Capital | $7,902 | $8,614 |
| Accumulated Deficit | $(50,379) | $(38,969) |
| Long-Term Debt | $0 | $1,002 |
Note: The company had no product revenue for either period. Operating expenses decreased slightly in 2025 primarily due to the absence of a $4.6 million warrant expense related to a termination agreement recorded in 2024.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $4.0 million (26%) year-over-year, driven largely by the non-recurrence of the $4.6 million warrant expense and $3.4 million mark-to-market adjustment on warrant liabilities recorded in 2024.
- Expense Composition: While total operating expenses declined slightly, Research and Development (R&D) expenses increased by 112% ($2.5 million) due to clinical trial execution and product development. General and Administrative (G&A) expenses increased by 31% ($1.6 million) due to higher compensation and professional fees, offset by a decrease in IPO-related advertising costs.
- Debt Elimination: The company extinguished all remaining convertible notes ($1.3 million principal) during the 2025 fiscal year through conversion to common stock, resulting in zero long-term debt on the balance sheet as of March 31, 2025.
- Capital Raising: The company completed a public offering in November 2024 raising approximately $10.0 million in gross proceeds and entered into an At-The-Market (ATM) sales agreement in February 2025.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management estimates current cash resources are sufficient to fund operations into, but not beyond, the first calendar quarter of 2026. The company projects a need for an additional $32 million to $40 million to fund operations through initial commercial launch. The company has no approved products and expects to continue incurring significant operating losses.
Key Risks and Contingencies:
- Going Concern: The company has an accumulated deficit of $50.4 million and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern without additional financing.
- Regulatory Approval: Success depends on obtaining FDA clearance (likely via De Novo pathway) for its sensing and ablation technology. There is no guarantee of approval or commercial viability.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including lack of segregation of duties and general technology controls. These weaknesses render disclosure controls and procedures ineffective.
- Manufacturing: The company relies on a single manufacturer for its lead product candidate and has limited experience in commercial-scale assembly.
- Stock Split Discrepancy: Following a 1-for-20 reverse stock split in October 2024, the company received a request from DTCC to issue 271,846 shares for fractional share rounding. Management disputes the calculation and has not issued the shares pending inquiry, creating potential liability.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter of 2026" liquidity estimate given the high burn rate and lack of revenue.
- Financing Plans: Assess the feasibility of raising the required $32–$40 million in the current market environment.
- Internal Controls: Review the remediation plan for material weaknesses in financial reporting and segregation of duties.
- Reverse Stock Split: Monitor the resolution of the fractional share rounding dispute with DTCC and potential dilution or liability.
- Clinical Progress: Track the status of the Proof of Concept (PoC) trials and the timeline for FDA De Novo submission.
- Warrant Liability: Confirm the classification and valuation of outstanding warrants (Series A, Pre-Funded, and Representative warrants) and their potential dilutive impact.